Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)

N/AEnrolling By InvitationNCT03968055

Stanford University100 enrolled

Overview

To determine if increased targeted contact between patients and the care team can improve diabetes outcomes in the 1st year after diagnosis. We will be using the GluVue platform to remotely view continuous glucose monitor (CGM) data.

Based on alerts from GluVue, care team members will proactively reach out to patients and their families for more frequent dose adjustments. We will assess if remote monitoring facilitates contact between the care team and patients and improves glycemic control.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

100

Conditions

Type 1 Diabetes

Interventions

Integration with EpicOTHER

Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic * Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic * Individuals who agree to CGM data integration into the electronic medical record (EMR) for remote monitoring * Age: birth to \< 21 years of age Exclusion Criteria: * Diabetes diagnosis other than T1D * Diagnosis of diabetes \> 1 month prior to initial visit * Individuals with the intention of obtaining diabetes care at another clinic * Individuals who do not consent to CGM use, CGM data integration, or remote monitoring * Individuals \> 21 years of age

Locations (1)

Lucile Packard Children's Hospital

Palo Alto, California, United States

Outcomes

Primary Outcomes

Contacts with the care provider

Prospective chart review to determine the number of contacts between the participant and care team due to remote monitoring

Time frame: 1 year

Secondary Outcomes

Hemoglobin A1c

Prospective chart review for lab values

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.